Pharmacotherapy of paediatric epilepsy

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 4, 2003, Pages 421-431

  Bergin, Ann M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Anticonvulsant; Child; Epilepsy; Pharmacotheraphy; Seizure

Indexed keywords

2 PYRROLIDONE DERIVATIVE; 4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CARBAMIC ACID DERIVATIVE; CLONAZEPAM; CORTICOTROPIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; MEPROBAMATE; MESUXIMIDE; N METHYL DEXTRO ASPARTIC ACID; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; SULFONAMIDE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANOREXIA; ANTICONVULSANT THERAPY; APLASTIC ANEMIA; ASTHENIA; ATAXIA; BENIGN CHILDHOOD EPILEPSY; BONE MARROW TOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILD DEVELOPMENT; CLINICAL TRIAL; COGNITION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; EMOTION; FATIGUE; FOCAL EPILEPSY; GASTROINTESTINAL DISEASE; GRAND MAL SEIZURE; HUMAN; HYPONATREMIA; INCIDENCE; INCREASED APPETITE; INFANTILE SPASM; INSOMNIA; LENNOX GASTAUT SYNDROME; LIVER TOXICITY; MYOCLONUS EPILEPSY; NONHUMAN; PHYSICAL DISABILITY; RASH; REMISSION; REVIEW; SEIZURE; SKIN MANIFESTATION; SLEEP DISORDER; SOCIAL ASPECT; SOCIOECONOMICS; SOMNOLENCE; TONIC CLONIC SEIZURE; VERTIGO; VISUAL FIELD DEFECT;

ANTICONVULSANTS; CHILD; DRUG THERAPY; EPILEPSY; EXPERT TESTIMONY; HUMANS; INCIDENCE; SEIZURES;

EID: 0037397810     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.4.421     Document Type: Review

References (91)

1. ANNEGERS JF: The epidemiology of epilepsy. In: The treatment of epilepsy. Wyllie E (Ed.), Lippincott Williams & Wilkins, BA, USA (1997):165-172.
2. DODSON WE: Pharmacokinetic principles of antiepileptic therapy in children. In: Pediatric epilepsy. diagnosis and therapy. Pellock JM, Dodson WE, Bourgeois BFD (Eds), Demos Medical Publishing Inc., NY, USA (2001):317-327.
3. SHORVON SD, REYNOLDS EH: Unnecessary polypharmacy for epilepsy. Br. Med. J. (1977) 1(6077):1635-1637.
4. CAMFIELD PR, CAMFIELD CS, GORDON K, DOOLEY JM: If a first antiepileptic drug fails to control a child's epilepsy, what are the chances of success with the next drug? J. Pediatr. (1997) 131(6):821-824.
5. SHINNAR S, BERG AT, TREIMAN DM et al.: Status epilepticus and tiagabine therapy: review of safety data and epidemiologic comparisons. Epilepsia (2001) 42(3):372-379.
6. LEIDERMAN DB: Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials. Epilepsia (1994) 35(Suppl. 5):S74-S76.
7. CHADW[CK DW, ANHUT H, GREINER MJ et al.: A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International gabapentin monotherapy study group 945-77. Neurology (1998) 51(5):1282-1288.
8. APPLETON R, FICHTNER K, LAMOREAUX L et all: Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin paediatric study group. Epilepsia (1999) 40(8):1147-1154.
9. TRUDEAU V, MYERS S, LAMOREAUX L et al.: Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J. Child NeuroL (1996) 11(6):470-475.
10. BOURGEOIS B, BROWN L, PELLOCK JM et al: Gabapentin (neurontin) monotherapy in children with benign childhood epilepsy with centrotemporal spikes (BECTS): a 36 week, double-blind, placebo-controlled study. Epilepsia (1998) 39(6):163.
11. WOLF SM, SHINNAR S, KANG H, GIL KB, MOSHE SL: Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia (1995) 36(12):1203-1205.
12. SCHMUTZ M, BRUGGER F, GENTSCH C, MCLEAN MJ, OLPE HR: Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia (1994) 35(Suppl. 5):S47-S50.
13. SACHDEO R, BEYDOUN A, SCHACHTER S et al: Oxcarbazepine (trileptal) as monotherapy in patients with partial seizures. Neurology (2001) 57(5):864-871.
14. SCHACHTER SC, VAZQUEZ B, FISHER RS et al.: Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology (1999) 52(4):732-737.
15. GLAUSER TA, NIGRO M, SACHDEO R et al: Adjunctive therapy with oxcarbazepine in children with partial seizures. The oxcarbazepine pediatric study group. Neurology (2000) 54(12):2237-2244.
16. BARCS G, WALKER EB, ELGER CE et al: Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia (2000) 41(12):1597-1607.
17. COENEN AM, BLEZER EH, VAN LUIJTELAAR EL: Effects of the gaba-uptake inhibitor tiagabine on electroencephalogram, spike-wave discharges and behaviour of rats. Epilepsy Res. (1995) 21(2):89-94.
18. UTHMAN BM, ROWAN AJ, AHMANN PA et al: Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch. Neural. (1998) 55(1):56-62.
19. VASQUEZ B, SACHDEO R, CHANG GY: Tiagabine or phenytoin as first add-on therapy of complex partial seizures. Neurology (1998) 50(Suppl. 4):A199.
20. ULDALL P, BULTEAU C, PEDERSEN SA, DULAC O, LYBY K: Tiagabine adjunctive therapy in children with refractory epilepsy: a single-blind dose escalating study. Epilepsy Res. (2000) 42(2-3):159-168.
21. SCHAPEL G, CHADWICK D: Tiagabine and non-convulsive status epilepticus. Seizure (1996) 5(2):153-156.
22. ETTINGER AB, BERNAL OG, ANDRIOLA MR et al.: Two cases of nonconvulsive status epilepticus in association with tiagabine therapy. Epilepsia (1999) 40(8):1159-1162.
23. KALVLAJNEN R, NOUSIAINEN I, MANTYJARVI M et al: Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology (1999) 53(5):922-926.
24. CHADWICK D: Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin european monotherapy study group. Lancet (1999) 354(9172):13-19.
25. DEAN C, MOSIER M, PENRY K: Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia (1999) 40(1):74-82.
26. NABBOUT RC, CHIRON C, MUMFORD J, DUMAS C, DULAC O: Vigabatrin in partial seizures in children. J Child Neurol. (1997) 12(3): 72-177.
27. GRAM L, SABERS A, DULAC O: Treatment of pediatric epilepsies with gamma-vinyl GABA (vigabatrin). Epilepsia (1992) 33(Suppl. 5):S26-S29.
28. APPLETON RE: The role of vigabatrin in the management of infantile epileptic syndromes. Neurology (1993) 43(Suppl. 5):S21-S23.
29. ULDALL P, ALVING J, GRAM L, HOGENHAVEN H: Vigabatrin in childhood epilepsy: a 5-year follow-up study. Neuropediatrics (1995) 26(5):253-256.
30. APPLETON RE, PETERS AC, MUMFORD JP, SHAW DE: Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia (1999) 40(11):1627-1633.
31. ELTERMAN RD, SHIELDS WD, MANSFIELD KA, NAKAGAWA J: Randomized trial of vigabatrin in patients with infantile spasms. Neurology (2001) 57(8):1416-1421.
32. CURATOLO P, VERDECCHIA M, BOMBARDIERI K: Vigabatrin for tuberous sclerosis complex. Brain Dev. (2001) 23(7):649-653.
33. GRANSTROM ML, GAILY E, LIUKKONEN E: Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms. Epilepsia (1999) 40(7):950-957.
34. MARCIANI MG, MASCHIO M, SPANEDDA F et ah Development of myoclonus in patients with partial epilepsy during treatment with vigabatrin: an electroencephalographic study. Acta Neurol. Scand. (1995) 91(1):1-5.
35. PANAYIOTOPOULOS CP, AGATHONIKOU A, SHAROQI IA, PARKER AP: Vigabatrin aggravates absences and absence status. Neurology (1997) 49(5):1467.
36. KRAUSS GL, JOHNSON MA, MILLER NR: Vigabatrin-associated retinal cone system dysfunction: electroretinogram and oplithalmologic findings. Neurology (1998) 50(3):614-618.
37. HARDUS P, VERDUIN WM, POSTMA G et al: Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia (2000) 41(5):581-587.
38. VANHATALO S, PAAKKONEN L, NOUSLUNEN I: Visual field constriction in children treated with vigabatrin. Neurology (1999) 52(8):1713-1714.
39. GROSS-TSUR V, BANIN E, SHAHAR E, SHALEV RS, LAHAT E: Visual impairment in children with epilepsy treated with vigabatrin. Ann. NeuroL (2000) 48(1):60-64.
40. HARDING GF, SPENCER EL, WILD JM, CONWAY M, BOHN RL: Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. NeuroLgy (2002) 58(8):1261-1265.
41. BOURGEOIS B, LEPPIK IE, SACKELLARES JC et al.: Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology (1993) 43(4):693-696.
42. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The felbarnate study group in Lennox-Gastaut syndrome. N. Engl. J. Med. (1993) 328(1):29-33.
43. DEVINSKY O, KOTHARI M, RUBIN R. Felbamate for absence seizures. Epilepsia (1992) 33(Suppl. 3):S84.
44. HURST DL, ROLAN TD: The use of felbamate to treat infantile spasms. J Child Neurol. (1995) 10(2):134-136.
45. GLAUSER TA, OLBERDING LS, TITANIC MK, PICCIRILLO DM: Felbamate in the treatment of acquired epileptic aphasia. Epilepsy Res. (1995) 20(1):85-89.
46. PELLOCK JM: Felbamate. Epilepsia (1999) 40(Suppl. 5):S57-S62.
47. COULTER DA: Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J. Child Neurol. (1997) 12(Suppl. 1):S2-S9.
48. MESSENHEIMER J, RAMSAY RE, WILLMORE LJ et al.: Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia (1994) 35(1):113-121.
49. DUCHOWNY M, PELLOCK JM, GRAF WD et al: A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal pediatric partial seizure study group. Neurology (1999) 53(8):1724-1731.
50. BERAN RG, BERKOVIC SF, DUNAGAN FM et al: Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia (1998) 39(12):1329-1333.
51. ERIKSSON AS, NERGARDH A, HOPPU K: The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia (1998) 39(5):495-501.
52. MOTTE J, TREVATHAN E, ARVIDSSON JF et al.: Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut study group. N. EngL J. Med. (1997) 337(25):1807-1812.
53. BRODIE MJ, RICHENS A, YUEN AW: Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK lamotrigine/carbamazepine monotherapy trial group. Lancet (1995) 345(8948):476-479.
54. STEINER TJ, DELLAPORTAS CI, FINDLEY LJ et aL: Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia (1999) 40(5):601-607.
55. GILLIAM F, VAZQUEZ B, SACKELLARES JC et al.: An active-control trial of lamotrigine monotherapy for partial seizures. Neurology (1998) 51(4):1018-1025.
56. FRANK LM, ENLOW T, HOLMES GL et al.: Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia (1999) 40(7):973-979.
57. FRANZ DN, TUDOR C, LEONARD J et al.: Lamotrigine therapy of epilepsy in tuberous sclerosis. Epilepsia (2001) 42(7):935-940.
58. VEGGIOTTI P, CIEUTA C, REX E, DULAC O: Lamotrigine in infantile spasms. Lancet (1994) 344(8933):1375-1376.
59. BRODIE MJ, YUEN AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 study group. Epilepsy Res. (1997) 26(3):423-432.
60. STEPHEN LJ, SILLS GJ, BRODIE MJ: Lamotrigine and topiramate may be a useful combination. Lancet (1998) 351(9107):958-959.
61. MEADOR KJ, LORING DW, RAY PG et al: Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology (2001) 56(9):1177-1182.
62. PELLOCK JM. Lamotrigine. In: Pediatric epilepsy: diagnosis and therapy. Pellock JM, Dodson WE, Bourgeois BFD (Eds), Demos Medical Publishing Inc., NY, USA (2001):461-466.
63. WONG IC, MAWER GE, SANDER JW: Factors influencing the incidence of lamotrigine-related skin rash. Ann. Pbarmacotber. (1999) 33(10):1037-1042.
64. SOTERO DE MENEZES MA, RHO JM, MURPHY P, CHEYETTE S: Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia (2000) 41(7):862-867.
65. BIRABEN A, ALLAIN H, SCARABIN JM, SCHUCK S, EDAN G: Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology (2000) 5500:1758.
66. DELORENZO RJ, SOMBATI S, COULTER DA: Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia (2000) 41(Suppl. 1):S40-S44.
67. GILLIAM FG, REIFE R, WU SC: Topiramate monotherapy: randomized controlled trial in patients with recently diagnosed localization-related epilepsy. Neurology (1999) 52(Suppl. 2):A248.
68. SACHDEO RC, GLAUSER TA, RITTER F et al: A double-blind, randomized trial of topiramate in lennox-gastaut syndrome. Topiramate YL study group. Neurology (1999) 52(9):1882-1887.
69. GLAUSER TA, CLARK PO, STRAWSBURG R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia (1998) 39(12):1324-1328.
70. BITON V. MONTOURIS GD, RITTER F et al.: A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC study group. Neurology (1999) 52(7):1330-1337.
71. SANKAR PS, PASQUALE LR, GROSSKREUTZ CL: Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch. Ophthalmol. (2001) 119(8):1210-1211.
72. TATUM WOT, FRENCH JA, FAUGHT E et al.: Postmarketing experience with topiramate and cognition. Epilepsia (2001) 42(9):1134-1140.
73. LUKYANETZ EA, SHKRYL VM, KOSTYUK PG: Selective blockade of N-type calcium channels by levetiracetam. Epilepsia (2002) 4300-18.
74. SHORVON SD, LOWENTHAL A, JANZ D, BIELEN E, LOISEAU P: Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European levetiracetam, study group. Epilepsia (2000) 41(9):1179-1186.
75. BEN-MENACHEM E, FALTER U: Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European levetiracetain study group. Epilepsia (2000) 41(10):1276-1283.
76. GLAUSER TA, PELLOCK JM, BEBIN EM et al.: Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia (2002) 43(5):518-524.
77. BOURGEOIS BFD, HOLDER DL, VALENCIA I et al: Open-label assessment of levetiracetam efficacy and adverse effects in a pediatric population. Epilepsia (2001) 42(Suppl. 7):S53-S54.
78. KOSSOFF EH, BERGEY GK, FREEMAN JM, VINING EP: Levetiracetam. psychosis in children with epilepsy. Epilepsia (2001) 42(12):1611-1613.
79. FRANZ DN, LEONARD JN, TUDOR CA, CHUCK F, EGELHOFF JC: Levetiracetam therapy of epilepsy in tuberous sclerosis. Epilepsia (2002) 43(Suppl. 7):S60.
80. SUZUKI S, KAWAKAMI K, NISHIMURA S et al.: Zonisamide blocks T-typc calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. (1992) 12(1):21-27.
81. PERUCCA E: The clinical pharmacokinetics of the new anti-epileptic drugs. Epilepsia (1999) 40(Suppl. 9):S7-S13.
82. LEPPIK IE, WILLMORE LJ, HOMAN RW et al.: Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res. (1993) 14(2):165-173.
83. FAUGHT E, AYALA R, MONTOURIS GG, LEPPIK IE: Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology (2001) 57(10):1774-1779.
84. KUMAGAI N, SEKI T, YAMAWAKI H et al.: Monotherapy for childhood epilepsies with zonisamide. Jpn. J. Psychiatry Neurol. (1991) 45(2):357-359.
85. SUZUKI Y. Zonisamide in west syndrome. Brain Dev. (2001) 23(7):658-661.
86. HENRY TR, LEPPIK IE, GUMNIT RJ, JACOBS M: Progressive myoclonus epilepsy treated with zonisamide. Neurology (1988) 38(6):928-931.
87. KYLLERMAN M, BEN-MENACHEM E: Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res. (1998) 29(2):109-114.
88. BERENT S, SACKELLARES JC, GIORDANI B et al.: Zonisamide (ci-912) and cognition: results from preliminary study. Epilepsia (1987) 28 (1):61-67.
89. CHARLES CL, STOESZ L, TOLLEFSON G: Zonisamide-induced mania. Psychosomatics (1990) 31(2):214-217.
90. KIMURA S: Zonisamide-induced behavior disorder in two children. Epilepsia (1994) 35(2):403-405.
91. SHIMIZU T, YAMASHITA Y, SATOI M et al: Heat stroke-like episode in a child caused by zonisamide. Brain Dev. (1997) 19(5):366-368.